Skip to main content
Erschienen in: Der Nervenarzt 12/2017

23.10.2017 | Botulinumtoxin | Aktuelles

Neues zur symptomatischen MS‑Therapie: Teil 2 – Gangstörung und Spastik

verfasst von: Prof. Dr. T. Henze, W. Feneberg, P. Flachenecker, D. Seidel, H. Albrecht, M. Starck, S. G. Meuth

Erschienen in: Der Nervenarzt | Ausgabe 12/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die symptomatische Behandlung der multiplen Sklerose (MS) hat heutzutage neben der Immuntherapie einen hohen Stellenwert im umfassenden Therapiekonzept dieser chronischen Erkrankung, trägt sie doch erheblich zu einer Verringerung von Beeinträchtigungen im Alltag, sozialen und beruflichen Leben sowie zur Verbesserung der Lebensqualität bei. Seit der letzten umfassenden Bestandsaufnahme 2004 in dieser Zeitschrift sowie den Leitlinien der Deutschen Gesellschaft für Neurologie/Klinisches Kompetenznetz Multiple Sklerose (DGN/KKN‑MS) zu Diagnose und Therapie der MS 2014 haben sich Neuerungen und Ergänzungen in den Bereichen Mobilität, Blasenfunktion, Sexualfunktionen, Augen, Fatigue, Kognition und Rehabilitation ergeben. Diese sowie weitere Aspekte (Messmethoden des jeweiligen Symptoms, Therapieziele, Gesamtbehandlungsplan) werden in einer Reihe aus 6 Einzelbeiträgen vorgestellt. Hier soll auf die Symptomatik von Gangstörung und Spastik eingegangen werden.
Literatur
2.
Zurück zum Zitat Fleuren JF, Voerman GE, Erren-Wolters CV et al (2010) Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 81:46–52CrossRefPubMed Fleuren JF, Voerman GE, Erren-Wolters CV et al (2010) Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 81:46–52CrossRefPubMed
3.
Zurück zum Zitat Henze T, von Mackensen S, Lehrieder G et al (2014) Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany. Health Qual Life Outcomes 12:119CrossRefPubMedPubMedCentral Henze T, von Mackensen S, Lehrieder G et al (2014) Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in Germany. Health Qual Life Outcomes 12:119CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Patejdl R, Tesar S, Zettl UK (2014) Multiple sclerosis, neuromyelitis optica and spasticity: control of specific symptoms and quality of life. Fortschr Neurol Psychiatr 82:373–385CrossRefPubMed Patejdl R, Tesar S, Zettl UK (2014) Multiple sclerosis, neuromyelitis optica and spasticity: control of specific symptoms and quality of life. Fortschr Neurol Psychiatr 82:373–385CrossRefPubMed
5.
Zurück zum Zitat Smania N, Picelli A, Munari D et al (2010) Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med 46:423–438PubMed Smania N, Picelli A, Munari D et al (2010) Rehabilitation procedures in the management of spasticity. Eur J Phys Rehabil Med 46:423–438PubMed
6.
Zurück zum Zitat Bobath B (1985) Abnormal postural reflex activity caused by brain lesion. Lippincott Williams & Wilkins, Philadelphia Bobath B (1985) Abnormal postural reflex activity caused by brain lesion. Lippincott Williams & Wilkins, Philadelphia
7.
Zurück zum Zitat Henze T, Rieckmann P, Toyka KV (2004) Symptomatische Therapie der Multiplen Sklerose. Nervenarzt 75((Supp.1):2–39PubMed Henze T, Rieckmann P, Toyka KV (2004) Symptomatische Therapie der Multiplen Sklerose. Nervenarzt 75((Supp.1):2–39PubMed
8.
Zurück zum Zitat Siev-Ner I, Gamus D, Lerner-Geva L et al (2003) Reflexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study. Mult Scler 9:356–361CrossRefPubMed Siev-Ner I, Gamus D, Lerner-Geva L et al (2003) Reflexology treatment relieves symptoms of multiple sclerosis: a randomized controlled study. Mult Scler 9:356–361CrossRefPubMed
9.
Zurück zum Zitat Velikonja O, Curic K, Ozura A et al (2010) Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg 112:597–601CrossRefPubMed Velikonja O, Curic K, Ozura A et al (2010) Influence of sports climbing and yoga on spasticity, cognitive function, mood and fatigue in patients with multiple sclerosis. Clin Neurol Neurosurg 112:597–601CrossRefPubMed
10.
Zurück zum Zitat Ahmadi A, Arastoo AA, Nikbakht M et al (2013) Comparison of the effect of 8 weeks aerobic and yoga training on ambulatory function, fatigue and mood status in MS patients. Iran Red Crescent Med J 15:449–454CrossRefPubMedPubMedCentral Ahmadi A, Arastoo AA, Nikbakht M et al (2013) Comparison of the effect of 8 weeks aerobic and yoga training on ambulatory function, fatigue and mood status in MS patients. Iran Red Crescent Med J 15:449–454CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Ghafari S, Ahmadi F, Nabavi M et al (2009) Effectiveness of applying progressive muscle relaxation technique on quality of life of patients with multiple sclerosis. J Clin Nurs 18:2171–2179CrossRefPubMed Ghafari S, Ahmadi F, Nabavi M et al (2009) Effectiveness of applying progressive muscle relaxation technique on quality of life of patients with multiple sclerosis. J Clin Nurs 18:2171–2179CrossRefPubMed
12.
Zurück zum Zitat Gunn H, Markevics S, Haas B et al (2015) Systematic review: the effectiveness of interventions to reduce falls and improve balance in adults with multiple sclerosis. Arch Phys Med Rehabil 96:1898–1912CrossRefPubMed Gunn H, Markevics S, Haas B et al (2015) Systematic review: the effectiveness of interventions to reduce falls and improve balance in adults with multiple sclerosis. Arch Phys Med Rehabil 96:1898–1912CrossRefPubMed
13.
Zurück zum Zitat Pearson M, Dieberg G, Smart N (2015) Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. Arch Phys Med Rehabil 96:1339–1348CrossRefPubMed Pearson M, Dieberg G, Smart N (2015) Exercise as a therapy for improvement of walking ability in adults with multiple sclerosis: a meta-analysis. Arch Phys Med Rehabil 96:1339–1348CrossRefPubMed
14.
Zurück zum Zitat Sosnoff JJ, Motl RW (2010) Effect of acute unloaded arm versus leg cycling exercise on the soleus H‑reflex in adults with multiple sclerosis. Neurosci Lett 479:307–311CrossRefPubMed Sosnoff JJ, Motl RW (2010) Effect of acute unloaded arm versus leg cycling exercise on the soleus H‑reflex in adults with multiple sclerosis. Neurosci Lett 479:307–311CrossRefPubMed
15.
Zurück zum Zitat Giesser B, Beres-Jones J, Budovitch A et al (2007) Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler 13:224–231CrossRefPubMed Giesser B, Beres-Jones J, Budovitch A et al (2007) Locomotor training using body weight support on a treadmill improves mobility in persons with multiple sclerosis: a pilot study. Mult Scler 13:224–231CrossRefPubMed
16.
Zurück zum Zitat Rampello A, Franceschini M, Piepoli M et al (2007) Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlled study. Phys Ther 87:545–555CrossRefPubMed Rampello A, Franceschini M, Piepoli M et al (2007) Effect of aerobic training on walking capacity and maximal exercise tolerance in patients with multiple sclerosis: a randomized crossover controlled study. Phys Ther 87:545–555CrossRefPubMed
17.
Zurück zum Zitat Coote S, Garrett M, Hogan N et al (2009) Getting the balance right: a randomised controlled trial of physiotherapy and exercise interventions for ambulatory people with multiple sclerosis. BMC Neurol 9:34CrossRefPubMedPubMedCentral Coote S, Garrett M, Hogan N et al (2009) Getting the balance right: a randomised controlled trial of physiotherapy and exercise interventions for ambulatory people with multiple sclerosis. BMC Neurol 9:34CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Schyns F, Paul L, Finlay K et al (2009) Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance. Clin Rehabil 23:771–781CrossRefPubMed Schyns F, Paul L, Finlay K et al (2009) Vibration therapy in multiple sclerosis: a pilot study exploring its effects on tone, muscle force, sensation and functional performance. Clin Rehabil 23:771–781CrossRefPubMed
19.
Zurück zum Zitat Mori F, Codeca C, Kusayanagi H et al (2010) Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. Eur J Neurol 17:295–300CrossRefPubMed Mori F, Codeca C, Kusayanagi H et al (2010) Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. Eur J Neurol 17:295–300CrossRefPubMed
20.
Zurück zum Zitat Miller L, Mattison P, Paul L et al (2007) The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 13:527–533CrossRefPubMed Miller L, Mattison P, Paul L et al (2007) The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 13:527–533CrossRefPubMed
21.
Zurück zum Zitat van der Linden ML, Hooper JE, Cowan P et al (2014) Habitual functional electrical stimulation therapy improves gait kinematics and walking performance, but not patient-reported functional outcomes, of people with multiple sclerosis who present with foot-drop. PLOS ONE 9:e103368CrossRefPubMedPubMedCentral van der Linden ML, Hooper JE, Cowan P et al (2014) Habitual functional electrical stimulation therapy improves gait kinematics and walking performance, but not patient-reported functional outcomes, of people with multiple sclerosis who present with foot-drop. PLOS ONE 9:e103368CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Otero-Romero S, Sastre-Garriga J, Comi G et al (2016) Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler 22:1386–1396CrossRefPubMed Otero-Romero S, Sastre-Garriga J, Comi G et al (2016) Pharmacological management of spasticity in multiple sclerosis: systematic review and consensus paper. Mult Scler 22:1386–1396CrossRefPubMed
23.
Zurück zum Zitat Formica A, Verger K, Sol JM et al (2005) Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial. Med Clin (Barc) 124:81–85CrossRef Formica A, Verger K, Sol JM et al (2005) Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial. Med Clin (Barc) 124:81–85CrossRef
24.
Zurück zum Zitat Collin C, Ehler E, Waberzinek G et al (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32:451–459CrossRefPubMed Collin C, Ehler E, Waberzinek G et al (2010) A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol Res 32:451–459CrossRefPubMed
25.
Zurück zum Zitat Novotna A, Mares J, Ratcliffe S et al (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18:1122–1131CrossRefPubMed Novotna A, Mares J, Ratcliffe S et al (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18:1122–1131CrossRefPubMed
26.
Zurück zum Zitat Wade DT, Collin C, Stott C et al (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16:707–714CrossRefPubMed Wade DT, Collin C, Stott C et al (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16:707–714CrossRefPubMed
28.
Zurück zum Zitat Patti F, Messina S, Solaro C et al (2016) Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry 87:944–951CrossRefPubMedPubMedCentral Patti F, Messina S, Solaro C et al (2016) Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J Neurol Neurosurg Psychiatry 87:944–951CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Zettl UK, Rommer P, Hipp P et al (2016) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord 9:9–30CrossRefPubMedPubMedCentral Zettl UK, Rommer P, Hipp P et al (2016) Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord 9:9–30CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Coghe G, Pau M, Corona F et al (2015) Walking improvements with nabiximols in patients with multiple sclerosis. J Neurol 262:2472–2477CrossRefPubMed Coghe G, Pau M, Corona F et al (2015) Walking improvements with nabiximols in patients with multiple sclerosis. J Neurol 262:2472–2477CrossRefPubMed
31.
Zurück zum Zitat Flachenecker P, Henze T, Zettl UK (2014) Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 72:95–102CrossRefPubMed Flachenecker P, Henze T, Zettl UK (2014) Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Eur Neurol 72:95–102CrossRefPubMed
32.
Zurück zum Zitat Koehler J, Feneberg W, Meier M et al (2014) Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci 124:652–656CrossRefPubMed Koehler J, Feneberg W, Meier M et al (2014) Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity. Int J Neurosci 124:652–656CrossRefPubMed
33.
Zurück zum Zitat Paolicelli D, Direnzo V, Manni A et al (2016) Long-term data of efficacy, safety, and tolerability in a real-life setting of THC/CBD oromucosal spray-treated multiple sclerosis patients. J Clin Pharmacol 56:845–851CrossRefPubMed Paolicelli D, Direnzo V, Manni A et al (2016) Long-term data of efficacy, safety, and tolerability in a real-life setting of THC/CBD oromucosal spray-treated multiple sclerosis patients. J Clin Pharmacol 56:845–851CrossRefPubMed
34.
Zurück zum Zitat Trojano MTHC (2016) CBD observational study data: evolution of resistant MS spasticity and associated symptoms. Eur Neurol 75(Suppl 1):4–8CrossRefPubMed Trojano MTHC (2016) CBD observational study data: evolution of resistant MS spasticity and associated symptoms. Eur Neurol 75(Suppl 1):4–8CrossRefPubMed
35.
Zurück zum Zitat Goodman AD, Brown TR, Edwards KR et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494–502CrossRefPubMed Goodman AD, Brown TR, Edwards KR et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494–502CrossRefPubMed
36.
Zurück zum Zitat Zorner B, Filli L, Reuter K et al (2016) Prolonged-release fampridine in multiple sclerosis: improved ambulation effected by changes in walking pattern. Mult Scler 22:1463–1475CrossRefPubMed Zorner B, Filli L, Reuter K et al (2016) Prolonged-release fampridine in multiple sclerosis: improved ambulation effected by changes in walking pattern. Mult Scler 22:1463–1475CrossRefPubMed
37.
Zurück zum Zitat Egeberg MD, Oh CY, Bainbridge JL (2012) Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances. Clin Ther 34:2185–2194CrossRefPubMed Egeberg MD, Oh CY, Bainbridge JL (2012) Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances. Clin Ther 34:2185–2194CrossRefPubMed
38.
Zurück zum Zitat Orsnes GB, Sorensen PS, Larsen TK et al (2000) Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 101:244–248CrossRefPubMed Orsnes GB, Sorensen PS, Larsen TK et al (2000) Effect of baclofen on gait in spastic MS patients. Acta Neurol Scand 101:244–248CrossRefPubMed
39.
Zurück zum Zitat Giovannelli M, Borriello G, Castri P et al (2007) Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 21:331–337CrossRefPubMed Giovannelli M, Borriello G, Castri P et al (2007) Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 21:331–337CrossRefPubMed
40.
Zurück zum Zitat Ochs G (1995) Die Behandlung der schweren Spastizität. Thieme, Stuttgart Ochs G (1995) Die Behandlung der schweren Spastizität. Thieme, Stuttgart
41.
Zurück zum Zitat Smail BD, Peskine A, Roche N et al (2006) Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler 12:101–103CrossRefPubMed Smail BD, Peskine A, Roche N et al (2006) Intrathecal baclofen for treatment of spasticity of multiple sclerosis patients. Mult Scler 12:101–103CrossRefPubMed
42.
Zurück zum Zitat Rekand T, Gronning M (2011) Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med 43:511–514CrossRefPubMed Rekand T, Gronning M (2011) Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med 43:511–514CrossRefPubMed
43.
Zurück zum Zitat Rommer PS, Kamin F, Abu-Mugheisib M et al (2016) Long-term effects of repeated cycles of Intrathecal triamcinolone acetonide on spasticity in MS patients. CNS Neurosci Ther 22:74–79CrossRefPubMed Rommer PS, Kamin F, Abu-Mugheisib M et al (2016) Long-term effects of repeated cycles of Intrathecal triamcinolone acetonide on spasticity in MS patients. CNS Neurosci Ther 22:74–79CrossRefPubMed
Metadaten
Titel
Neues zur symptomatischen MS‑Therapie: Teil 2 – Gangstörung und Spastik
verfasst von
Prof. Dr. T. Henze
W. Feneberg
P. Flachenecker
D. Seidel
H. Albrecht
M. Starck
S. G. Meuth
Publikationsdatum
23.10.2017
Verlag
Springer Medizin
Erschienen in
Der Nervenarzt / Ausgabe 12/2017
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI
https://doi.org/10.1007/s00115-017-0439-3

Weitere Artikel der Ausgabe 12/2017

Der Nervenarzt 12/2017 Zur Ausgabe

Mitteilungen der DGPPN

Mitteilungen der DGPPN 12/2017

Mitteilungen der DGN

Mitteilungen der DGN

Passend zum Thema

ANZEIGE
OnSite Advertorial Multiple Sklerose
Service mit Mehrwert

Services in der MS-Therapie für Neurolog*innen und Betroffene

Diagnose und Therapie der MS können für Patient*innen und Neurolog*innen mit Herausforderungen einhergehen [1,2]. Mit umfangreichen Servicemaßnahmen klärt Biogen Ärztinnen und Ärzte über mögliche Therapieoptionen auf und unterstützt diese bei der Fortbildung sowie Betroffene im Alltag.